Biomarkers in Urine Samples From Patients With Wilms Tumor
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.
Genetic: proteomic profiling
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis
Other: medical chart review
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics|
- Wilms tumor biomarkers identified by ELISA [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2012|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- To validate the prognostic performance of specific-candidate Wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs) in urine specimens collected at diagnosis from 50 patients with favorable histology Wilms tumor who relapsed and 50 patients who did not relapse.
OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01550393
|Principal Investigator:||Elizabeth A. Mullen, MD||Dana-Farber Cancer Institute|